Literature DB >> 19015955

The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms.

Selma Sahin1, Leslie Z Benet.   

Abstract

Half-life (t (1/2)) is the oldest but least well understood pharmacokinetic parameter, because most definitions are related to hypothetical 1-compartment body models that don't describe most drugs in humans. Alternatively, terminal half-life (t (1/2,z)) is utilized as the single defining t (1/2) for most drugs. However, accumulation at steady state may be markedly over predicted utilizing t (1/2, z). An apparent multiple dosing half-life (t (1/2, app)) was determined from peak and trough steady-state ratios and found to be significantly less than reported terminal t (1/2)s for eight orally dosed drugs with t (1/2,z) values longer than one day. We define a new parameter, "operational multiple dosing half-life" (t (1/2, op)), as equal to the dosing interval at steady-state where the maximum concentration at steady-state is twice the maximum concentration found for the first dose. We demonstrate for diazepam that the well-accepted concept that t (1/2,z) representing the great majority of the AUC will govern accumulation can be incorrect. Using oral diazepam, we demonstrate that t (1/2, op) is remarkably sensitive to the absorption t (1/2), even when this absorption t (1/2) is much less than t (1/2,z,) and describe the relevance of this in designing extended release dosage forms. The t (1/2, op) is compared with previously proposed half-lives for predicting accumulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19015955      PMCID: PMC3581066          DOI: 10.1007/s11095-008-9787-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  20 in total

Review 1.  Context-sensitive half-times: what are they and how valuable are they in anaesthesiology?

Authors:  James M Bailey
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Optimal extravascular dosing intervals.

Authors:  P Veng-Pedersen; N B Modi
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

3.  A model based assessment of redistribution dependent elimination and bioavailability of rifabutin.

Authors:  R C Li; P K Narang; I Poggesi; M Strolin-Benedetti
Journal:  Biopharm Drug Dispos       Date:  1996-04       Impact factor: 1.627

4.  An improved intercept method for the assessment of absorption rate in bioequivalence studies.

Authors:  P Macheras; M Symillides; C Reppas
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

5.  Dosage intervals based on mean residence times.

Authors:  J G Wagner
Journal:  J Pharm Sci       Date:  1987-01       Impact factor: 3.534

6.  Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects.

Authors:  A Hsu; G R Granneman; G Witt; C Locke; J Denissen; A Molla; J Valdes; J Smith; K Erdman; N Lyons; P Niu; J P Decourt; J B Fourtillan; J Girault; J M Leonard
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

7.  Effective half-life in clinical pharmacology.

Authors:  H Boxenbaum; M Battle
Journal:  J Clin Pharmacol       Date:  1995-08       Impact factor: 3.126

8.  Chiral bioequivalence: effect of absorption rate on racemic etodolac.

Authors:  J R Boni; J M Korth-Bradley; L S Richards; S T Chiang; D R Hicks; L Z Benet
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

9.  Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration.

Authors:  J J Zimmerman; B D Kahan
Journal:  J Clin Pharmacol       Date:  1997-05       Impact factor: 3.126

10.  Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

Authors:  M Iwamoto; L A Wenning; A S Petry; M Laethem; M De Smet; J T Kost; S A Merschman; K M Strohmaier; S Ramael; K C Lasseter; J A Stone; K M Gottesdiener; J A Wagner
Journal:  Clin Pharmacol Ther       Date:  2007-08-22       Impact factor: 6.875

View more
  35 in total

1.  First-dose pharmacokinetics of lithium carbonate in children and adolescents.

Authors:  Robert L Findling; Cornelia B Landersdorfer; Vivian Kafantaris; Mani Pavuluri; Nora K McNamara; Jon McClellan; Jean A Frazier; Linmarie Sikich; Robert Kowatch; Jacqui Lingler; Jon Faber; Perdita Taylor-Zapata; William J Jusko
Journal:  J Clin Psychopharmacol       Date:  2010-08       Impact factor: 3.153

Review 2.  Benet L Z and Galeazzi R L: noncompartmental determination of the steady-state volume of distribution, J Pharm Sci 68, 1071-1074, 1979--the backstory.

Authors:  Leslie Z Benet
Journal:  AAPS J       Date:  2012-06       Impact factor: 4.009

Review 3.  Rate and extent of drug accumulation after multiple dosing revisited.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

4.  Flip-flop kinetics of ropivacaine during continuous epidural infusion influences its accumulation rate.

Authors:  Maria Cusato; Massimo Allegri; Tekla Niebel; Pablo Ingelmo; Monica Broglia; Antonio Braschi; Mario Regazzi
Journal:  Eur J Clin Pharmacol       Date:  2010-11-16       Impact factor: 2.953

5.  Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuation.

Authors:  Anita Grover; Leslie Z Benet
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-04-16       Impact factor: 2.745

6.  Time of effect duration and administration interval for sitagliptin in patients with kidney failure.

Authors:  Frieder Keller; Bertram Hartmann; David Czock
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-12-19       Impact factor: 2.441

Review 7.  The role of transporters in the pharmacokinetics of orally administered drugs.

Authors:  Sarah Shugarts; Leslie Z Benet
Journal:  Pharm Res       Date:  2009-06-30       Impact factor: 4.200

8.  Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.

Authors:  L Lalande; L Bourguignon; S Bihari; P Maire; M Neely; R Jelliffe; S Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

9.  Dedication to professor Leslie Z. Benet: 50 years of scientific excellence and still going strong!

Authors:  David E Smith; Malcolm Rowland; Kathleen M Giacomini; Gordon L Amidon
Journal:  Pharm Res       Date:  2012-07-20       Impact factor: 4.200

10.  Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.

Authors:  Sharon M Seifert; Xinhui Chen; Amie L Meditz; Jose R Castillo-Mancilla; Edward M Gardner; Julie A Predhomme; Carolyn Clayton; Gregory Austin; Brent E Palmer; Jia-Hua Zheng; Brandon Klein; Becky J Kerr; L Anthony Guida; Caitlin Rower; Joseph E Rower; Jennifer J Kiser; Lane R Bushman; Samantha MaWhinney; Peter L Anderson
Journal:  AIDS Res Hum Retroviruses       Date:  2016-09-19       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.